BioBusiness

But are innovations sufficient to increase adoption? CMOs are demanding better continuous bioprocessing options.

NIH trial shows remdesivir accelerates recovery; Gilead study shows similar efficacy for 5- and 10-day dosing.

Experts to discuss strategies for ensuring supply of quality drug products during a pandemic in April 28 online event.

Successful negotiation of life-sciences collaboration agreements involves careful planning.

The company closed two new funds, ARCH Venture Fund X and ARCH Venture Fund X Overage, for a total of $1.46 billion combined.

Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.

As politicians focus on drug cost reduction, biopharmaceutical companies in the US are moving to states with lower taxes and relocating some facilities that had been offshore.

As the coronavirus pandemic unfolds, the bio/pharma industry must practice science over hype.

Johnson & Johnson announces clinical trial plans for COVID-19 vaccine candidate, as well as plans to produce 1 billion vaccine doses.

Research from data and analytics company GlobalData shows that CAR-T cell therapy innovations across APAC will make the global market for these therapies more competitive.

As patent disputes within the scientific community continue, drug developers consider the intellectual property unknowns associated with this emerging technology.

Emergency actions to protect patients and the drug supply may have long-term implications.

Technology and capacity investments create opportunities in the cell and gene therapy arena for CDMOs and biopharma alike.

The company has said that all three of its operating sites in China started back up on Feb. 12 and that it is closely monitoring the outbreak.

As politicians focus on drug cost reduction, biopharmaceutical companies in the US are moving to states with lower taxes, and relocating some facilities that had been offshore.

Catalent builds on its investment in cell and gene therapy development and manufacturing with the acquisition of MaSTherCell Global.

The formation of the new gene therapy company stems from the progress and success of Nationwide Children’s Hospital’s clinical manufacturing and gene therapy work.

Karen Flynn rejoins Catalent as president of biologics operations; regional presidents named for US and Europe.

The new business unit, as well as a new leadership team formed by AbbVie, will be effective upon closing of the acquisition in the first quarter of 2020.

Tim Howard will assume the role of acting ISPE CEO and president after John Bournas steps down from the positions.

The joint venture will develop next-generation cell and gene therapies incorporating Affimer proteins.

The promise of new therapies is tempered by the need for affordability, safety, and ethics.

With a positive employment market, some biopharma professionals explore options for career advancement.

The new scientific advisory board will oversee innovation projects, identify and develop key new technologies, and be responsible for forming high-caliber alliances with innovative start-ups.

Under the restructuring, Sanofi will gain sole global rights to Kevzara (sarilumab) and sole ex-US rights to Praluent (alirocumab), while Regeneron will gain sole US rights to Praluent.